Invest in 10,000+ US Stocks and ETFs
* Offering through VF Securities, Inc. (member FINRA/SIPC)
Ionis Pharmaceuticals, Inc. discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an antisense injection for the treatment of polyneuropathy caused by hereditary transthyretin amyloidosis in adults; and WAYLIVRA, an antisense medicine for treatment for familial chylomicronemia syndrome (FCS) and familial partial lipodystrophy. It also develops medicines for various indications that are in phase 3 study, including Eplontersen as a monthly self-administered subcutaneous injection to treat all types of ATTR; Olezarsen for patients with FCS and severe hypertriglyceridemia (SHTG); Donidalorsen for patients with hereditary angioedema; ION363 for patients with amyotrophic lateral sclerosis; Tofersen to inhibit the production of superoxide dismutase 1; Pelacarsen for patients with established cardiovascular disease and elevated lipoprotein(a); and Bepirovirsen to inhibit the production of viral proteins associated with hepatitis B virus. In addition, the company develops IONIS-FB-LRx to inhibit the production of complement factor B and the alternative complement pathway; and ION224 to reduce the production of diacylglycerol acyltransferase 2. It has a strategic collaboration with Biogen for the treatment of neurological disorders; and collaboration and license agreement with Metagenomi, Inc, AstraZeneca, Bayer AG, GlaxoSmithKline plc, Novartis, Roche, Swedish Orphan Biovitrum AB, and PTC Therapeutics. The company was incorporated in 1989 and is based in Carlsbad, California. more
Time Frame | IONS | Sector | S&P500 |
---|---|---|---|
1-Week Return | -4.58% | -2.06% | -0.55% |
1-Month Return | 7.47% | -1.92% | 2.72% |
3-Month Return | -14.42% | -10.4% | 7.66% |
6-Month Return | -10.8% | -4.6% | 10.15% |
1-Year Return | -28.52% | 4.06% | 27.53% |
3-Year Return | 12.54% | 1.94% | 32.31% |
5-Year Return | -41.54% | 36.48% | 89.2% |
10-Year Return | -39.13% | 97.46% | 194.59% |
Dec '19 | Dec '20 | Dec '21 | Dec '22 | Dec '23 | 5YR TREND | |
---|---|---|---|---|---|---|
Total Revenue | 1.12B | 729.00M | 810.00M | 587.00M | 787.65M | [{"date":"2019-12-31","value":100,"profit":true},{"date":"2020-12-31","value":64.92,"profit":true},{"date":"2021-12-31","value":72.13,"profit":true},{"date":"2022-12-31","value":52.27,"profit":true},{"date":"2023-12-31","value":70.14,"profit":true}] |
Cost of Revenue | 4.00M | 12.00M | 11.00M | 14.00M | 9.13M | [{"date":"2019-12-31","value":28.57,"profit":true},{"date":"2020-12-31","value":85.71,"profit":true},{"date":"2021-12-31","value":78.57,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":65.24,"profit":true}] |
Gross Profit | 1.12B | 717.00M | 799.00M | 573.00M | 778.51M | [{"date":"2019-12-31","value":100,"profit":true},{"date":"2020-12-31","value":64.08,"profit":true},{"date":"2021-12-31","value":71.4,"profit":true},{"date":"2022-12-31","value":51.21,"profit":true},{"date":"2023-12-31","value":69.57,"profit":true}] |
Gross Margin | 99.64% | 98.35% | 98.64% | 97.61% | 98.84% | [{"date":"2019-12-31","value":100,"profit":true},{"date":"2020-12-31","value":98.71,"profit":true},{"date":"2021-12-31","value":98.99,"profit":true},{"date":"2022-12-31","value":97.96,"profit":true},{"date":"2023-12-31","value":99.19,"profit":true}] |
Operating Expenses | 753.00M | 889.00M | 829.00M | 984.00M | 1.13B | [{"date":"2019-12-31","value":66.51,"profit":true},{"date":"2020-12-31","value":78.52,"profit":true},{"date":"2021-12-31","value":73.22,"profit":true},{"date":"2022-12-31","value":86.91,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] |
Operating Income | 366.00M | (172.00M) | (30.00M) | (411.00M) | (353.73M) | [{"date":"2019-12-31","value":100,"profit":true},{"date":"2020-12-31","value":-46.99,"profit":false},{"date":"2021-12-31","value":-8.2,"profit":false},{"date":"2022-12-31","value":-112.3,"profit":false},{"date":"2023-12-31","value":-96.65,"profit":false}] |
Total Non-Operating Income/Expense | (67.77M) | (42.99M) | (8.16M) | 144.08M | (61.73M) | [{"date":"2019-12-31","value":-47.03,"profit":false},{"date":"2020-12-31","value":-29.84,"profit":false},{"date":"2021-12-31","value":-5.66,"profit":false},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":-42.84,"profit":false}] |
Pre-Tax Income | 347.00M | (170.00M) | (30.00M) | (258.00M) | (333.96M) | [{"date":"2019-12-31","value":100,"profit":true},{"date":"2020-12-31","value":-48.99,"profit":false},{"date":"2021-12-31","value":-8.65,"profit":false},{"date":"2022-12-31","value":-74.35,"profit":false},{"date":"2023-12-31","value":-96.24,"profit":false}] |
Income Taxes | 44.00M | 317.00M | (1.00M) | 12.00M | 32.32M | [{"date":"2019-12-31","value":13.88,"profit":true},{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":-0.32,"profit":false},{"date":"2022-12-31","value":3.79,"profit":true},{"date":"2023-12-31","value":10.2,"profit":true}] |
Income After Taxes | 303.00M | (487.00M) | (29.00M) | (270.00M) | (366.29M) | [{"date":"2019-12-31","value":100,"profit":true},{"date":"2020-12-31","value":-160.73,"profit":false},{"date":"2021-12-31","value":-9.57,"profit":false},{"date":"2022-12-31","value":-89.11,"profit":false},{"date":"2023-12-31","value":-120.89,"profit":false}] |
Income From Continuous Operations | 303.26M | (486.77M) | (28.60M) | (269.72M) | (366.29M) | [{"date":"2019-12-31","value":100,"profit":true},{"date":"2020-12-31","value":-160.51,"profit":false},{"date":"2021-12-31","value":-9.43,"profit":false},{"date":"2022-12-31","value":-88.94,"profit":false},{"date":"2023-12-31","value":-120.78,"profit":false}] |
Income From Discontinued Operations | - | - | - | - | - | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}] |
Net Income | 294.00M | (487.00M) | (29.00M) | (270.00M) | (366.29M) | [{"date":"2019-12-31","value":100,"profit":true},{"date":"2020-12-31","value":-165.65,"profit":false},{"date":"2021-12-31","value":-9.86,"profit":false},{"date":"2022-12-31","value":-91.84,"profit":false},{"date":"2023-12-31","value":-124.59,"profit":false}] |
EPS (Diluted) | 2.20 | (0.36) | (0.38) | (2.89) | (2.56) | [{"date":"2019-12-31","value":100,"profit":true},{"date":"2020-12-31","value":-16.36,"profit":false},{"date":"2021-12-31","value":-17.27,"profit":false},{"date":"2022-12-31","value":-131.36,"profit":false},{"date":"2023-12-31","value":-116.36,"profit":false}] |
These ratios help you determine the liquidity of the company. Higher is better.
IONS | |
---|---|
Cash Ratio | 8.15 |
Current Ratio | 8.91 |
Quick Ratio | 8.82 |
These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.
IONS | |
---|---|
ROA (LTM) | -7.25% |
ROE (LTM) | -73.38% |
These ratios help you understand the company's liabilities, gauging the riskiness of the investment.
IONS | |
---|---|
Debt Ratio Lower is generally better. Negative is bad. | 0.78 |
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. | 0.22 |
These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.
IONS | |
---|---|
Trailing PE | NM |
Forward PE | 90.91 |
P/S (TTM) | 7.41 |
P/B | 8.98 |
Price/FCF | NM |
EV/R | 6.12 |
EV/Ebitda | NM |
PEG | 25.70 |
Ionis Pharmaceuticals Inc (IONS) share price today is $36.25
Yes, Indians can buy shares of Ionis Pharmaceuticals Inc (IONS) on Vested. To buy Ionis Pharmaceuticals Inc from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in IONS stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.
Yes, you can purchase fractional shares of Ionis Pharmaceuticals Inc (IONS) via the Vested app. You can start investing in Ionis Pharmaceuticals Inc (IONS) with a minimum investment of $1.
You can invest in shares of Ionis Pharmaceuticals Inc (IONS) via Vested in three simple steps:
The 52-week high price of Ionis Pharmaceuticals Inc (IONS) is $54.44. The 52-week low price of Ionis Pharmaceuticals Inc (IONS) is $33.33.
The price-to-earnings (P/E) ratio of Ionis Pharmaceuticals Inc (IONS) is
The price-to-book (P/B) ratio of Ionis Pharmaceuticals Inc (IONS) is 8.98
The dividend yield of Ionis Pharmaceuticals Inc (IONS) is 0.00%
The market capitalization of Ionis Pharmaceuticals Inc (IONS) is $6.02B
The stock symbol (or ticker) of Ionis Pharmaceuticals Inc is IONS